| 國立臺灣大學 |
2010 |
Safety and Efficacy of Intravenous Colistin (Colistin Methanesulphonate) for Severe Multidrug-Resistant Gram-Negative Bacterial Infections
|
盛望徽; 王振泰; 陳宜君; 張上淳; SHENG, WANG-HUEI; WANG, JANN-TAY; CHEN, YEE-CHUN; CHANG, SHAN-CHWEN |
| 臺大學術典藏 |
2020-12-30T02:43:37Z |
Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections
|
SHAN-CHWEN CHANG; Chen Y.-C.; Wang J.-T.; Cheng C.-Y.; Sheng W.-H. |
| 臺大學術典藏 |
2021-02-26T02:00:09Z |
Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections
|
Cheng C.-Y.;Wang-Huei Sheng;Wang J.-T.;Chen Y.-C.;Chang S.-C.; Cheng C.-Y.; WANG-HUEI SHENG; Wang J.-T.; Chen Y.-C.; Chang S.-C. |
| 臺大學術典藏 |
2021-05-06T01:52:31Z |
Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections
|
Cheng C.-Y.; Sheng W.-H.; Wang J.-T.; YEE-CHUN CHEN; Chang S.-C. |
| 臺大學術典藏 |
2020-09-29T01:47:58Z |
Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections
|
Chang S.-C.; YEE-CHUN CHEN; Wang J.-T.; Sheng W.-H.; Cheng C.-Y. |
| 臺大學術典藏 |
2022-05-13T08:04:59Z |
Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections
|
Cheng C.-Y.; Sheng W.-H.; JANN-TAY WANG; Chen Y.-C.; Chang S.-C. |
| 臺大學術典藏 |
2019-02-13T05:00:44Z |
Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2
|
TSEN-FANG TSAI; TSEN-FANG TSAI |
| 臺大學術典藏 |
2018 |
Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: Week 52 results from SPIRIT-P2
|
Genovese M.C.;Combe B.;Kremer J.M.;Tsen-Fang Tsai;Behrens F.;Adams D.H.;Lee C.;Kerr L.;Nash P.; Genovese M.C.; Combe B.; Kremer J.M.; TSEN-FANG TSAI; Behrens F.; Adams D.H.; Lee C.; Kerr L.; Nash P. |
| 臺大學術典藏 |
2022-03-22T08:28:50Z |
Safety and efficacy of kartigen? in treating cartilage defects: A randomized, controlled, phase i trial
|
Liu Y.-L;Yen C.-C;Liu T.-S.T;Chang C.-H;Shih T.T.-F;Wang J.-H;Yang M.-C;Lin F.-H;Liu H.-C.; Liu Y.-L; Yen C.-C; Liu T.-S.T; Chang C.-H; Shih T.T.-F; Wang J.-H; Yang M.-C; Lin F.-H; Liu H.-C.; FENG-HUEI LIN |
| 臺大學術典藏 |
2022-03-22T08:31:52Z |
Safety and efficacy of kartigen? in treating cartilage defects: A randomized, controlled, phase i trial
|
Liu Y.-L;Yen C.-C;Liu T.-S.T;Chang C.-H;Shih T.T.-F;Wang J.-H;Yang M.-C;Lin F.-H;Liu H.-C.; Liu Y.-L; Yen C.-C; Liu T.-S.T; Chang C.-H; Shih T.T.-F; Wang J.-H; Yang M.-C; Lin F.-H; Liu H.-C.; FENG-HUEI LIN |
| 臺大學術典藏 |
2022-03-22T08:31:54Z |
Safety and efficacy of kartigen? in treating cartilage defects: A randomized, controlled, phase i trial
|
Liu Y.-L;Yen C.-C;Liu T.-S.T;Chang C.-H;Shih T.T.-F;Wang J.-H;Yang M.-C;Lin F.-H;Liu H.-C.; Liu Y.-L; Yen C.-C; Liu T.-S.T; Chang C.-H; Shih T.T.-F; Wang J.-H; Yang M.-C; Lin F.-H; Liu H.-C.; FENG-HUEI LIN |
| 臺大學術典藏 |
2021-12-16T03:30:15Z |
Safety and Efficacy of Kartigen® in Treating Cartilage Defects: A Randomized, Controlled, Phase I Trial
|
Liu, Yen-Liang; Yen, Chun-Che; Liu, Tzu-Shang Thomas; Chang, Chih-Hung; TIFFANY TING-FANG SHIH; Wang, Jyh-Horng; Yang, Ming-Chia; Lin, Feng-Huei; Liu, Hwa-Chang |
| 臺大學術典藏 |
2021-09-21T23:19:59Z |
Safety and efficacy of kartigen® in treating cartilage defects: A randomized, controlled, phase i trial
|
Liu, Yen Liang; Yen, Chun Che; Liu, Tzu Shang Thomas; Chang, Chih Hung; TIFFANY TING-FANG SHIH; JYH-HORNG WANG; Yang, Ming Chia; Lin, Feng-Huei; Liu, Hwa Chang |
| 臺大學術典藏 |
2022-09-20T03:08:13Z |
Safety and Efficacy of Kartigen® in Treating Cartilage Defects: A Randomized, Controlled, Phase I Trial
|
Liu, Yen-Liang; Yen, Chun-Che; Liu, Tzu-Shang Thomas; Chang, Chih-Hung; Shih, Tiffany Ting-Fang; JYH-HORNG WANG; Yang, Ming-Chia; Lin, Feng-Huei; Liu, Hwa-Chang |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT
|
Okusaka T.; Ikeda K.; Kudo M.; Finn R.; Qin S.; Han K.-H.; ANN-LII CHENG; Piscaglia F.; Kobayashi M.; Sung M.; Chen M.; Wyrwicz L.; Yoon J.-H.; Ren Z.; Mody K.; Dutcus C.; Tamai T.; Ren M.; Hayato S.; Kumada H. |
| 嘉南藥理大學 |
2015-08 |
Safety and efficacy of manual syringe infusion of distending media for hysteroscopic procedures: a case-control study
|
Ting, Wan-Hua; Lin, Ho-Hsiung; Wu, Ming-Ping; Tu, Fung-Chao; Peng, Fu-Shiang; Hsiao, Sheng-Mou |
| 臺大學術典藏 |
2018-09-10T15:28:25Z |
Safety and efficacy of manual syringe infusion of distending media for hysteroscopic procedures: A case-control study
|
HO-HSIUNG LIN; Ting, W.-H. and Lin, H.-H. and Wu, M.-P. and Tu, F.-C. and Peng, F.-S. and Hsiao, S.-M. |
| 臺大學術典藏 |
2020-02-17T08:50:52Z |
Safety and efficacy of manual syringe infusion of distending media for hysteroscopic procedures: A case-control study
|
Peng F.-S; Hsiao S.-M.; Tu F.-C; Wu M.-P; HO-HSIUNG LIN; Ting W.-H |
| 臺大學術典藏 |
2021-03-03T03:00:57Z |
Safety and efficacy of manual syringe infusion of distending media for hysteroscopic procedures: A case-control study
|
Ting W.-H.; HO-HSIUNG LIN; Wu M.-P.; Tu F.-C.; Peng F.-S.; Hsiao S.-M. |
| 臺北醫學大學 |
2009 |
Safety and efficacy of mixing cetrorelix with follitropin alfa -a randomized study
|
曾啟瑞 |
| 臺北醫學大學 |
2009 |
Safety and efficacy of mixing cetrorelix with follitropin alfa: a randomized study
|
溫永銳; Lin YH; Wen YR; Chang Y; Seow KM; Hsieh BC; Hwang JL; Tzeng CR |
| 中國醫藥大學 |
2010-06 |
Safety and efficacy of mixing cetrorelix with follitropin alfa: a randomized study
|
林禹宏(Yu-Hung Lin); 溫永銳(Yeong-Ray Wen); (Yuanmay Chang); 蕭國明(Kok-Min Seow); 謝碧純(Bih-Chwen Hsieh); 黃建榮(Jiann-Loung Hwang)*; (Chii-Ruey Tzeng) |
| 臺大學術典藏 |
2021-04-23T05:56:29Z |
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
|
Tan D.S.-W.;Leighl N.B.;Riely G.J.;Chih-Hsin Yang;Sequist L.V.;Wolf J.;Seto T.;Felip E.;Aix S.P.;Jonnaert M.;Pan C.;Tan E.Y.;Ko J.;Moody S.E.;Kim D.-W.; Tan D.S.-W.; Leighl N.B.; Riely G.J.; CHIH-HSIN YANG; Sequist L.V.; Wolf J.; Seto T.; Felip E.; Aix S.P.; Jonnaert M.; Pan C.; Tan E.Y.; Ko J.; Moody S.E.; Kim D.-W. |
| 國家衛生研究院 |
2018-12-19 |
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase 2 trial (AT
|
Boku, N;Ryu, MH;Kato, K;Chung, HC;Minashi, K;Lee, KW;Cho, H;Kang, WK;Komatsu, Y;Tsuda, M;Yamaguchi, K;Hara, H;Fumita, S;Azuma, M;Chen, LT;Kang, YK |
| 國立成功大學 |
2019 |
Safety and efficacy of nivolumab in combination with s-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (a
|
Boku, N.;Ryu, M.-H.;Kato, Kato K.;Chung, H.C.;Minashi, K.;Lee, K.-W.;Cho, H.;Kang, W.K.;Komatsu, Y.;Tsuda, M.;Yamaguchi, K.;Hara, Hara H.;Fumita, S.;Azuma, M.;Chen, L.-T.;Kang, Y.-K. |
